ClinicalTrials.gg
Status unknownNCT05061147Updated Oct 1, 2021

A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

A Phase 1/2 interventional study of MAX-40279-01 in Leukemia, Acute Myeloid Leukemia and Relapsed/Refractory Acute Myeloid Leukemia, sponsored by Maxinovel Pty., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-01.

Primary conditionLeukemia, Myeloid, AcuteRegistry: LeukemiaReclassifiedWhy we changed it
Registry
Leukemia — the first condition term the registry derived for this study.
ClinicalTrials.gg
Leukemia, Myeloid, Acute
Why
  1. The study's listed conditions name Leukemia, Myeloid, Acute, a narrower term within Leukemia.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Maxinovel Pty., Ltd. · Phase 1/2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Sep 2021), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 473 studies in Leukemia, Myeloid, Acute with a site in China — 265 open to participants now, 289 under way, 40 of them phase 3. Leukemia, Myeloid, Acute · China.

Planned enrollment
125th of 433
100 · median 50
Started
2021
with 43 others
Phase 1/2
66 of 473
39 open now
Registered
151st of 473
by date

Among the 473 studies in Leukemia, Myeloid, Acute with a site in China, this one is the 125th largest by planned enrollment of the 433 interventional ones that give a count, is one of 44 that started in 2021, is one of 66 in phase 1/2, and was the 151st registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

265 of the 473 studies in Leukemia, Myeloid, Acute with a site in China are open now. Recruiting first, the newest first:

260 more — sign in →

All 265 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 473 studies in Leukemia, Myeloid, Acute with a site in China, or all of them as a file.
02

Study summary

This study is a phase Ib/II study of Max-40279-01 in combination with Azacitidine (AZA) in patients with Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML). This study include Phase Ib and Phase II study. The phase Ib study is designed to evaluate the safety and tolerability of MAX-40279-01 in combination with Azacitidine (AZA) in patients with Relapsed or Refractory AML. The phase II study is designed to preliminarily assess the efficacy and safety of Max-40279-01 in combination with Azacitidine (AZA) in patients with Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML).

Read the detailed description

This is a two-part study comprised of a dose escalation part and a dose expansion part.

03

Conditions studied

  • Leukemia
  • Acute Myeloid Leukemia
  • Relapsed/Refractory Acute Myeloid Leukemia
  • Myelodysplastic Syndrome

Browse trials for

Keywords

  • Relapsed/Refractory Acute Myeloid Leukemia
  • Myelodysplastic Syndrome
04

In context

Leukemia, Myeloid, Acute Reclassified

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

This study's planned enrollment of 100 is above the median of 40 across 3,007 interventional studies indexed under Leukemia, Myeloid, Acute.

Browse Leukemia, Myeloid, Acute studies →

Lead sponsor

Maxinovel Pty., Ltd. is the lead sponsor of 12 studies on the registry; 1 is open to participants now.

Compared within Leukemia, Myeloid, Acute, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Leukemia. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and/or females over age 18
  2. A diagnosis of AML according to the World Health Organization (WHO) 2016 criteria with disease and have exhausted, or are ineligible for therapeutic options, or int-risk or high-risk or very high-risk MDS according to revised International Prognostic Scoring System (IPSS-R);
  3. (ECOG) performance status of 0-2.
  4. Expected survival >3 months.
  5. No radiotherapy, surgery or hormonal therapy for any kind of within 2 weeks prior to participating in this study. Patients must have fully recovered from the acute toxicities of any prior treatment with any anti-cancer drugs (including hypomethylating agents in MDS patients), radiotherapy or other anti-cancer modalities (i.e., returned to baseline status as noted before most recent treatment) for any tumors. Patients with persisting, stable chronic toxicities from such prior treatment ≤Grade 1 are eligible, but must be documented as such.
  6. Signed form.

Exclusion criteria

Exclusion Criteria:

  1. Acute promyelocytic leukemia according to World Health Organization 2016 criteria
  2. Known central nervous system involvement
  3. Medical history of difficulty swallowing, malabsorption or other chronic gastrointestinal disease, or conditions that may hamper compliance and/or absorption of the tested product
  4. Known allergies, , or intolerance to Max-40279-01 or AZA or the of these treatments
  5. Previously treated other than the current disease, except for adequately treated non-melanoma skin cancer, in situ cancer, or other cancer from which the subject has been disease-free for at least 5 years at the trial entry
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Max-40279-01 in combination with Azacitidine (AZA)

    This is an open-label Phase Ib/II clinical study. The study will be conducted in two parts: Part I: Phase Ib dose escalation. Participants receive Max-40279-01 in combination with azacytidine (AZA), with different dose schedules. Part II: Phase II dose expansion. Participants divide into positive group and negative group according to whether FLT3 gene mutation occurs, approximately 40 people per group. All participants receive the recommended dose for Part 2 of Max-40279-01 with azacytidine (AZA).

    Drug: MAX-40279-01

Interventions

  • Drug: AZA AZA will be administered at 75 mg/m\^2 by subcutaneous injection for 7 consecutive days from D1 to D7 in 28-day treatment cycles. Other Name: Azacitidine Drug: Max-40279-01 Max-40279-01 will be administered as a combination of multiple oral capsules containing 5 and 25 mg. An alternate combination of 35 mg, 50 mg and 60 mg Max-40279-01 twice a day may be utilized. Other Name: NA

    Also known as: Azacitidine (AZA)

07

What researchers measure

Primary outcomes

  1. Maximum tolerated dose (MTD)

    To explore the maximum tolerable dose (MTD) of Max-40279-01 in combination with Azacitidine (AZA) for patients with r/r AML or MDS, the recommended phase II dose (RP2D).

    Time frame: Through study Part 1 completion, an average of 6 months

  2. Phase II dose (RP2D)

    Recommended phase II dose (RP2D)

    Time frame: Through study Part 1 completion, an average of 6 months

  3. Overall survival(OS)

    Time frame: Up to 24 months

  4. Rate of complete remission (CRc)

    including Complete Remission with incomplete Platelet recovery (CRp) and Complete Remission with incomplete hematologic recovery (CRi)

    Time frame: Up to 24 months

Secondary outcomes

  1. Tmax

    Time to maximum plasma concentration

    Time frame: Approximately 4 weeks

  2. Cmax

    Maximum plasma drug concentration

    Time frame: Approximately 4 weeks

  3. AUC

    Area under the time-concentration curve

    Time frame: Approximately 4 weeks

  4. t1/2

    Observed terminal half-life

    Time frame: Approximately 4 weeks

  5. Objective response rate (ORR)

    The ORR is defined as the proportion of subjects with confirmed CR or confirmed PR, based on IRWG.

    Time frame: 1 months (anticipated)

  6. Safety and tolerability assessed by incidence and severity of adverse events

    All grade ≥ 3 toxicities according to CTCAE (Common Terminology Criteria for Adverse Events) version 5 will be tabulated

    Time frame: 24 months

08

Study locations

1 of 1 sites recruiting
  • Institute of Hematology & Blood Diseases Hospital
    Tianjin, China
    Recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2021 (actual). Primary completion is estimated for Apr 2022, 7 months after the start.

Of 92 industry-sponsored phase 1/2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 73 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 91. This study's planned 7 months is below that.

Counting every sponsor, half of 226 studies reached it within 73 months; a quarter within 48 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2021
First posted
Sep 29, 2021
StartActual
Sep 16, 2021
Primary completionEst.
Apr 30, 2022
CompletionEst.
Oct 31, 2022
Last update
Oct 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05061147
Lead sponsor
Maxinovel Pty., Ltd.
Responsible party
Sponsor
First posted
Sep 29, 2021
Start date
Sep 16, 2021
Primary completion
Apr 30, 2022 (estimated)
Completion
Oct 31, 2022 (estimated)
Last update
Oct 1, 2021

Study contacts

Hanying Bao, MD,Ph.D
Contact
hybao@maxinovel.com
+86-021-51370693

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nefextinib

Start the discussion